Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Citius Oncology, Inc. (CTOR) vs InterCure Ltd. (INCR)

Citius Oncology, Inc. and InterCure Ltd. are both Drug Manufacturers Specialty & Generic companies. Citius Oncology, Inc. is the larger, with a market value of $97.6M against $62.3M — 1.6× the size. Citius Oncology, Inc. has negative trailing earnings, so its P/E is not meaningful; InterCure Ltd. trades at 9.8×. InterCure Ltd. has the higher net margin (4.88% vs 0.00%) and the higher return on invested capital (0.00% vs −67.2%). Across the 11 metrics below, InterCure Ltd. leads on 11 and Citius Oncology, Inc. on 0.

Valuation

Metric CTOR INCR Drug Manufacturers Specialty & Generic median
P/E n/m 9.84 20.14
P/S n/m 1.98 2.25
P/B 2.81 1.96 1.90
Price to free cash flow n/m n/m 16.54
EV/EBITDA n/m 23.47 12.29
EV/Sales n/m 2.12 2.56
Earnings yield (44.76%) 10.16% (2.99%)
Free cash flow yield (28.37%) (0.34%) 0.00%

Profitability

Metric CTOR INCR Drug Manufacturers Specialty & Generic median
Gross margin — 32.74% 53.94%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 4.88% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (126.58%) 0.00% (0.40%)
Return on assets (45.20%) 0.00% (3.32%)
Return on invested capital (67.15%) 0.00% 0.00%

Growth

Metric CTOR INCR Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) — 16.15% 10.01%
EPS growth (last fiscal year) (9.68%) 52.50% —
Revenue growth, 5-year CAGR — 31.11% 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CTOR INCR Drug Manufacturers Specialty & Generic median
Debt to equity 0.50 0.27 0.05
Current ratio 0.73 1.85 2.31
Net debt to EBITDA (0.40) (4.07) 0.85

Dividend

Metric CTOR INCR Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio — 0.00 0.00

Size

Metric CTOR INCR Drug Manufacturers Specialty & Generic median
Market cap 97.63m 62.33m 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack